Much excitement has built in recent years on the new class of incretin drugs that include glucagon-like-peptide-1 inhibitor ...

Medical experts discuss whether GLP-1 medications, including Mounjaro and Zepbound, could become comprehensive treatments for ...

Researchers are exploring a novel quintuple agonist that targets five pathways, including GLP-1R, GIPR, and three PPARs. This ...

Dr Shivani Misra is a clinical associate professor and honorary consultant in diabetes at Imperial College London ...

A compound comprising five agonists that together tackle weight loss, glucose reduction, insulin sensitization, and blood fat ...

Eli Lilly and Company (NYSE: LLY) today announced detailed results from SURPASS-PEDS, the first Phase 3 trial to evaluate the ...

Ozempic, marketed by Novo Nordisk in India, is primarily indicated for the treatment of type 2 diabetes. While it can lead to ...

Scientists have created a pre-clinical weight loss drug combining GLP-1, GIP, glucagon and peptide YY hormones to match ...

Weight loss can be a challenge, even for those who eat healthily and exercise regularly. But injectable type 2 diabetes medications — also known as GLP-1 and GIP injections — are changing the way we ...

The WHO has added GLP-1 agonists to its Essential Medicines List in 2025. Learn more about the impact of this decision.

Interest in GLP-1 medications like Ozempic will continue to grow given the multiple health conditions they can improve. In recent years, the growing list of medical benefits for GIP and GLP-1 agonists ...

BERLIN — A novel glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor dual agonist combined into a single drug (LY3298176, Lilly), dubbed a "twincretin," ...